Trade Summary

6 days ago, Boulding Mark Elliott, serving as EXEC. VP AND CLO at PTC THERAPEUTICS, INC. (PTCT), sold 10,462 shares at $78.65 per share, for a total transaction value of $822,867.75. Following this transaction, Boulding Mark Elliott now holds 105,272 shares of PTCT.

This sale represents a 9.04% decrease in Boulding Mark Elliott's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, June 17, 2026 and publicly disclosed via SEC Form 4 filing on Monday, June 22, 2026 at 5:20 PM ET, 5 days after the trade was made.

PTC THERAPEUTICS, INC. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.